DAYTONA BEACH, FL — (Marketwired) — 04/30/15 — (OTCQB: QUTR) (“Quture” or “Q”) the proven and experienced clinical performance and outcome analytics and solutions company in health care, today announced filing a provisional patent application (apparatus and method) for its extensive intellectual property (IP).
The transformative and disruptive technology claimed in the patent application is for Quture–s complete solution, the QualOptima Connectivity & Analytics System. The IP is for all customer segments of Quture to strategically optimize value and to achieve optimal clinical, operational, and financial outcomes and individual patient health. The claims include the core intellectual capital proven in the formal Clinical Trial at the University of Miami, Miller School of Medicine and Jackson Memorial Hospital under the direction of Keith Candiotti, MD, Executive Vice Chair & Chief Operating Officer, Vice Chair, Clinical Research, Department of Anesthesiology.
Quture–s filing for its intellectual property embedded in QualOptima follows on the US Supreme Court decision in the Alice case establishing what is patentable. Joseph F. Kincart, JD, Ideation Law , with extensive expertise and experience in patent law, represents Quture in its intellectual property and filed “A System for Quantification of Health Care Quality and Predictive Healthcare Value, Quality and Outcomes of Healthcare of an Individual Patient.”
“We are excited and proud to file our intellectual capital claims so we can more openly demonstrate this novel technology to potential customers. This IP is fundamental to achieving market recognition of the ultimate market potential and value of the Company,” said Landon Feazell, Chairman & CEO of Quture. “The value of this IP is essential to the market cap of Quture and transitioning to revenue. We are focused on our Go to Market strategies, which Quture will now pursue even more aggressively with this protection of our invention and system. This is a major milestone for Quture.”
Feazell discussed the significance of the intellectual capital in the patent at length. “Last year in a keynote speech at HIMSS, the then President of the American Medical Association explained the need for a data and analytics layer that sits on top of electronic medical records, pulling data from multiple sources for analytics and to connect people, providers and payers to essential clinical information. Data is just that until analytics transforms it to knowledge, and just as important, until that insight is used to improve care and outcomes while reducing costs in health care. The reason healthcare quality and patient safety have not improved significantly is because the technologies that have existed didn–t provide that knowledge and insight. They have used billing and claims data, not even entered until the patient is out of the hospital or left the physician–s care. QualOptima is based on the performance and outcomes measures developed by organized medicine, precise numerators and denominator metrics. Quture technology is different because we first calibrate those performance and outcomes metrics to the specific patient–s predictive risk factors for patient-centered care and analysis. Our analytics system is based on over 35 years of reviewing the care at hundreds of hospitals by thousands of physicians to hundreds of thousands of patients. The IP in the patent filed is the complete solution we have been developing over those years, now with standardized metrics that can be used retrospectively for value-based payment, to improve quality and patient safety but ultimately in real-time for patient care and management. With Quture–s big data analytics technologies, the insight from the QualOptima system exceeds our expectations to transform care and value-driven payment for services. Physicians will use the data to increase their revenues with PQRS data, while hospitals will use the data to comply with Joint Commission Standards for performance evaluation and outcomes improvement. QualOptima will connect every customer segment in health, wellness and health care to clinical information essential to them. What we know from manually developing such insight is that with the QualOptima electronic data capture technologies, Quture–s solution provides the clinical knowledge to understand and change the extreme variances in patient outcomes and the cost for that care — to achieve optimal value in health care and optimal health of individual patients.”
As the free enterprise solution to improving health and health care while reducing costs, Quture is positioned through its disruptive technology to become the foremost global provider of patient-centric, value-based clinical intelligence and knowledge solutions. Additional patent claims are made in the application require the core IP, so Quture envisions future patent filings for a patent “thicket” of interlocking patents with Mr. Kincart. Quture is aggressively pursuing funding to complete development of prototypes for proctoring use of medical devices, a peri-operative outcomes application, expanding predictive risk factors to wellness and fitness factors (engaging patients using smart watches and remote patient monitoring), patient-centered individualized care plans, machine learning for big data analytics, and a personalized medicine subsidiary.
“These prototypes in development rely on the intellectual property in this initial patent application,” said Feazell. “We intend to file subsequent patents definitely stating the claims inherent in the complete solution envisioned for the QualOptima data and analytics platform and expanding on the claims in this patent application.”
Quture International (OTCQB: QUTR) is the proven and experienced clinical performance and outcome analytics and solutions company in American healthcare. Quture–s first-to-market clinical intelligence software is the complete solution for healthcare providers, payers, employers, and insurance companies seeking to achieve optimal clinical, financial and operational outcomes. Q–s QualOptima Connectivity & Analytics System empowers value-driven, patient-centered, personalized care focused on real-time and predictive patient management and patient safety, with optimal quality demonstrated by outcomes correlated with resource use, revenue and cost. As an Application Partner of InterSystems Corporation, Quture–s software operates on their HealthShare strategic technology platform to capture, integrate, aggregate, and analyze data transformed to knowledge in its innovative second-generation database. Quture–s core competence and value proposition lies in its embedded evidence-based metrics, clinical content and analytic algorithms developed from over 35 years of measuring performance in hundreds of hospitals, physician organizations and HMO–s.
As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned through its disruptive technology to become the foremost global provider of value-based clinical intelligence and knowledge solutions. Q is a Nevada corporation based in Daytona Beach, Florida, and trades on the OTC exchange under the symbol –QUTR.–
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.
For Further Information Contact:
Quture Investor Relations
Phone: 844.276.4192
Email:
You must be logged in to post a comment Login